84 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28085275	53	Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.	Bristol-Myers Squibb
27073051	71	Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.	Bristol-Myers Squibb
26704266	80	Novel phenylalanine derived diamides as Factor XIa inhibitors.	Bristol-Myers Squibb
25592713	37	Pyridine and pyridinone-based factor XIa inhibitors.	Bristol-Myers Squibb
26005539	23	Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.	Bristol-Myers Squibb
25990761	66	Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin.	Institute For Infection Research
25881820	62	Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors.	Bristol-Myers Squibb R & D
25728130	79	Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.	Bristol-Myers Squibb
25405503	109	Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.	Bristol-Myers Squibb
25179681	81	Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.	Chinese Academy of Sciences
24102612	105	Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity.	University of Bari &Quot;Aldo Moro&Quot
23927973	41	Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.	Bristol-Myers Squibb Research & Development
23478148	10	Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor.	Bristol-Myers Squibb Pharmaceutical Research Institute
23602442	28	Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.	Bristol-Myers Squibb
16644215	52	Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.	Celera Genomics
22770607	54	Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.	Virginia Commonwealth University
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
17588746	103	SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.	Bristol-Myers Squibb
15837303	52	Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors.	Berlex Biosciences
14640539	112	Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).	Pharmaceutical Research Institute
12954057	113	Polymer-assisted solution-phase library synthesis and crystal structure of alpha-ketothiazoles as tissue factor VIIa inhibitors.	Pharmacia
11170646	106	Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.	Dupont Pharmaceuticals
12824035	39	Polymer-assisted solution-phase (PASP) parallel synthesis of an alpha-ketothiazole library as tissue factor VIIa inhibitors.	Pharmacia
12270173	23	Targeting thrombin and factor VIIa: design, synthesis, and inhibitory activity of functionally relevant indolizidinones.	Universit£
22041058	44	Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.	Bristol-Myers Squibb
21641796	30	Design, synthesis and biological activity of novel peptidyl benzyl ketone FVIIa inhibitors.	Technical University of Denmark
20102150	35	Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.	Johnson & Johnson Pharmaceutical Research and Development
19447619	3	Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety.	University of New Orleans
	37	Synthesis and biological activity of P2–P4 azapeptidomimetic P1-argininal and P1-ketoargininamide derivatives: a novel class of serine protease inhibitors	TBA
19128974	28	Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.	Daiichi Sankyo
18674905	58	Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.	Chugai Pharmaceutical
15332844	8	Dysinosins B-D, inhibitors of factor VIIa and thrombin from the Australian sponge Lamellodysidea chlorea.	Griffith University
18159923	24	7-fluoroindazoles as potent and selective inhibitors of factor Xa.	Johnson & Johnson Pharmaceutical Research and Development
17643988	92	Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.	Bristol-Myers Squibb
17566736	60	Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa.	Pfizer
16714109	40	Design of novel, potent, and selective human beta-tryptase inhibitors based on alpha-keto-[1,2,4]-oxadiazoles.	Celera
16650987	10	Efforts toward oral bioavailability in factor VIIa inhibitors.	Celera
16458507	2	Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.	Celera Genomics
16257204	37	Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.	Celera
16213711	37	Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
15913999	8	Structure-based design and synthesis of pyrazinones containing novel P1 'side pocket' moieties as inhibitors of TF/VIIa.	Pfizer
15203149	72	Structure-based design of amidinophenylurea-derivatives for factor VIIa inhibition.	Aventis Pharma Deutschland
14552766	12	Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex.	Pharmacia
12699744	15	Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo.	Genentech
12668013	42	Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors.	Aventis Pharma Deutschland
12593666	30	Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor.	Senju Pharmaceutical
12270169	13	Albumin affinity tags increase peptide half-life in vivo.	Genentech
11689072	49	Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.	Axys Pharmaceuticals
11527709	19	Optimization of a screening lead for factor VIIa/TF.	Axys Pharmaceuticals
32527459	67	Discovery of hydroxy pyrimidine Factor IXa inhibitors.	Merck
32340773	110	Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants.	Merck
32551603	185	Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.	Novartis Institutes For Biomedical Research
32456431	24	Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.	Bristol Myers Squibb
31445854	43	Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.	Bristol-Myers Squibb
10212122	35	Secondary structure peptide mimetics: design, synthesis, and evaluation of beta-strand mimetic thrombin inhibitors.	Molecumetics
30446438	36	Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.	China Pharmaceutical University
9873692	54	Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa.	Dupont Pharmaceuticals
29400967	136	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.	Bristol-Myers Squibb
31833761	32	Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.	Bristol-Myers Squibb
9871540	100	Pyrazoles, 1,2,4-triazoles, and tetrazoles as surrogates for cis-amide bonds in boronate ester thrombin inhibitors.	Dupont Pharmaceuticals
31563807	63	Discovery of novel, potent, isosteviol-based antithrombotic agents.	Peking University
26575094	60	Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.	University of Antwerp (Ua)
29501396	59	Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.	Bristol-Myers Squibb
28780160	14	Macrocyclic factor XIa inhibitors.	Bristol-Myers Squibb
29517911	87	Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.	Bicycle Therapeutics
29077405	63	Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).	Bristol-Myers Squibb
28460818	29	Neutral macrocyclic factor VIIa inhibitors.	Bristol-Myers Squibb Research and Development
9802391	31	The cloned guinea pig pancreatic polypeptide receptor Y4 resembles more the human Y4 than does the rat Y4.	Uppsala University
9195867	15	Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D.	University of California Berkeley
20383151	2	Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.	Dana-Farber Cancer Institute
19648931	16	Design, synthesis and selection of DNA-encoded small-molecule libraries.	Praecis Pharmaceuticals
19305397	22	Molecular docking and ligand specificity in fragment-based inhibitor discovery.	University of California San Francisco
19699645	12	Design, synthesis, and biological evaluation of hydroquinone derivatives as novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase.	Northern Kentucky University